One patient achieved a complete response, and 10 had a partial response. Enfortumab vedotin may be a treatment option for patients with advanced head and neck cancer that is not amenable to definitive ...

This study will focus on the treatment of newly diagnosed locally advanced primary head and neck cancer patients with no ...

The following is a summary of "Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and ...

With over 300 new cases diagnosed in New Zealand each year, mouth cancer often goes undetected until it has reached an advanced stage, significantly lowering survival rates. The goal of this year's ...

Results of a study recently published in the journal JCO Precision Oncology show that in the clinical trial context, combined ...

Co-authored by investigators of VHIO's Cancer Genomics Group and Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, results of a ...

Co-authored by investigators of VHIO’s Cancer Genomics Group and Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, results of a study recently published open access as an Original ...

Lack of health insurance coverage accounts for a considerable proportion of racial and ethnic disparities in the diagnosis of advanced-stage cancer, according to researchers.

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2024 and ...

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant ...

The SITC posters will be available on ImCheck's corporate website after the poster sessions have been opened.